Article Text

PDF
Original article
Anti-tumour necrosis factor agents reduce non-steroidal anti-inflammatory drug-induced small bowel injury in rheumatoid arthritis patients
  1. Toshio Watanabe1,
  2. Tetsuya Tanigawa1,
  3. Masatsugu Shiba1,
  4. Yuji Nadatani1,
  5. Yasuaki Nagami1,
  6. Satoshi Sugimori1,
  7. Hirokazu Yamagami1,
  8. Kenji Watanabe1,
  9. Kazunari Tominaga1,
  10. Yasuhiro Fujiwara1,
  11. Tatsuya Koike2,
  12. Tetsuo Arakawa1
  1. 1Department of Gastroenterology, Osaka City University Graduate School of Medicine, Osaka, Japan
  2. 2Department of Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan
  1. Correspondence to Dr Toshio Watanabe, Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan; watanabet{at}med.osaka-cu.ac.jp

Abstract

Objective The role of tumour necrosis factor α (TNFα) in the pathogenesis of non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal damage remains unclear. We evaluated the preventive effect of anti-TNF therapy against NSAID-induced enteropathy in rheumatoid arthritis (RA) patients.

Design Capsule endoscopy was performed in 95 consecutive RA patients who received NSAID for more than 3 months, with or without anti-TNF therapy over a period of 3 months. The findings were scored from 0 to 4: 0, normal; 1, red spots; 2, one to four erosions; 3, more than four erosions; and 4, large erosions/ulcers. The relationship between the use of anti-TNF therapy and the risk of severe damage (scores 3 or 4) or the most severe damage (score 4) was assessed using multiple logistic regression analysis. Furthermore, a propensity score matching analysis was performed to reduce the effects of TNF selection bias.

Results By stratifying the patients on the basis of anti-TNF therapy, we obtained crude OR of 0.23 for severe damage (95% CI 0.09 to 0.65) and 0.37 for the most severe damage (95% CI 0.16 to 0.86). This protective effect of anti-TNF therapy remained robust to adjustments for baseline characteristics, with the adjusted OR for severe damage and the most severe damage ranging from 0.23 to 0.26 and 0.06 to 0.41, respectively. Propensity score matching yielded similar results and showed the protective effects of anti-TNF therapy against severe and most severe damage.

Conclusions Anti-TNF therapy may protect against NSAID-induced small intestinal damage in RA patients.

  • TNF-ALPHA
  • ENTEROPATHY
  • NON-STEROIDAL ANTI-INFLAMMATORY DRUGS
  • SMALL BOWEL DISEASE
  • ENDOSCOPY

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.